From: Prognostic value of Kindlin-2 expression in patients with solid tumors: a meta-analysis
Study (Author and year) | n | Age (years or numbers): [mean or median (range)] (cut-off: low/high) | Sex (M/F) | Histological differentiation (I/II/III) | Tumor size (cm) (cut-off) (low/high) | Tumor category (grade) | Lymphatic invasion (∓) | Vascular invasion (low/high) | Metastasis (∓) | Staging method | Stage (cut-off) | Other therapy (no/yes) |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Yoshida et al. 2017 (I) [14] | 79 | 65 (mean) (41–85) (65):39/40 | 51/28 | 9/63/7 | NR | NR | 19/60 | 32/47 | NR | NR | NR | C: 9/70 R: 68/11 |
Zhan et al. 2015 [15] | 31 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
Mahawithitwong et al. 2013 [16] | 95 | 65 (mean) (36–86) (65): 52/43 | 58/37 | 10/33/52 | NR | (T1/2/3/4) 9/3/82/1 | 34/61* | 38/57 | NR | UICC | NR | C: 10/85 R: 78/17 |
Cao et al. 2015 (II) [17] | 110 | (58): 55/55 | 80/30 | 33/67/10 | (3, 5) 32/45/11 | (T1, 2/3, 4) 7/103 | 57/53 | NR | NR | TNM | (IIB/IIIA) 59/51 | 99/12 |
Cao et al. 2015 (III)[17] | 147 | (58): 79/68 | 113/34 | 23/109/15 | (3, 5) 38/71/36 | (T1, 2/3, 4) 20/127 | 64/83 | NR | NR | TNM | (IIB/IIIA) 70/77 | 104/43 |
Wu et al. 2017 [18] | 203 | (65): 109/94 | 165/38 | (Low/high) 96/107* | (3) 140/63 | NR | NR | NR | NR | TNM | (I/II) 8/115* | NR |
Papachristou et al. 2008 [19] | 60 | 54 (mean) (21–85) | 34/26 | 20/29/11* | (8) 23/37 | NR | NR | NR | NR | NR | NR | NR |
Ge et al. 2015 [20] | 72 | (53): 35/37 | 60/12 | NR | (5) 29/43* | NR | NR | Cap: 44/28* Mic: 49/23* | NR | TNM | (II/III) 41/31 | NR |
Lin et al. 2017 [21] | 127 | (60): 111/16 | 17/110 | NR | (3) 10/117 | NR | NR | Cap: 40/87 Mic: 66/61* | 9/115* | NR | (II/III) 11/116 | NR |
Ning et al. 2017 [22] | 100 | (18): 40/60 | 68/32 | (Low/high) 15/85* | NR | NR | NR | NR | 60/40* | NR | NR | RC: 50/50* |
Ou et al. 2016 [23] | 188 | 39 (mean) (39): 98/90* | 103/85 | NR | NR | NR | NR | NR | NR | NR | (II/III) 85/103* | NR |
Ren et al. 2014 [24] | 113 | (50): 28/85* | −/113 | (Low/high) 26/87* | NR | NR | NR | NR | 49/34 | FIGO | (I/II/III/IV) 9/13/73/10 | RC: 21/68 |
Shen et al. 2012 [25] | 40 | 67 (mean) (47–93) (60): 14/26 | 30/10 | 4/8/28 | NR | (T1, 2/3, 4) 8/32* | N1/2/3 21/10/9* | NR | 37/3 | Pathologic | (II/III) 8/32* | NR |
Li et al. 2017 [26] | 109 | (60):62/47 | 67/42 | 36/41/32* | NR | (Tx/1/2/34) 4/68/20/17 | Nx/0/1 2/99/8* | NR | NR | AJCC | (II/III) 70/39 | NR |
Yan et al. 2016 [27] | 336 | (65):177/159 | 240/96 | NR | (4) 176/160 | (T1, 2/3, 4) 167/169 | 202/134 | NR | 269/67* | TNM | (II/III) 124/212* | NR |